Paper34599863
Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S and 7 others. Cancer Med, 2021. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy. Papers, record 34599863. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34599863
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Non-Small-Cell Lung | Major topic |
| Genomics | Major topic |
| Immunotherapy | Major topic |
| Lung Neoplasms | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Asian People | |
| Cohort Studies | |
| Female | |
| Genetic Profile | |
| Humans | |
| Male | |
| Middle Aged | |
| Progression-Free Survival | |
| Young Adult |
Source PubMed
References54
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23988776 | EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. | Eur Respir J | 2014 | https://conductscience.org/library/papers/23988776 | PubMed |
| 2 | 25535693 | Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. | J Thorac Oncol | 2015 | https://conductscience.org/library/papers/25535693 | PubMed |
| 3 | 31297240 | Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion. | ESMO Open | 2019 | https://conductscience.org/library/papers/31297240 | PubMed |
| 4 | 15647370 | Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. | Proc Natl Acad Sci U S A | 2005 | https://conductscience.org/library/papers/15647370 | PubMed |
| 5 | 30902917 | Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer. | Oncologist | 2019 | https://conductscience.org/library/papers/30902917 | PubMed |
| 6 | 26051236 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26051236 | PubMed |
| 7 | 15696205 | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. | PLoS Med | 2005 | https://conductscience.org/library/papers/15696205 | PubMed |
| 8 | 12032546 | p53 Stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. | Nat Cell Biol | 2002 | https://conductscience.org/library/papers/12032546 | PubMed |
| 9 | 15118125 | EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. | Science | 2004 | https://conductscience.org/library/papers/15118125 | PubMed |
| 10 | 24346090 | Large-scale screening and molecular characterization of EML4-ALK fusion variants in archival non-small-cell lung cancer tumor specimens using quantitative reverse transcription polymerase chain reaction assays. | J Thorac Oncol | 2014 | https://conductscience.org/library/papers/24346090 | PubMed |
| 11 | 23723294 | Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). | Ann Oncol | 2013 | https://conductscience.org/library/papers/23723294 | PubMed |
| 12 | 29989075 | GeneFuse: detection and visualization of target gene fusions from DNA sequencing data. | Int J Biol Sci | 2018 | https://conductscience.org/library/papers/29989075 | PubMed |
| 13 | 22761469 | Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. | Clin Cancer Res | 2012 | https://conductscience.org/library/papers/22761469 | PubMed |
| 14 | 22327623 | RET, ROS1 and ALK fusions in lung cancer. | Nat Med | 2012 | https://conductscience.org/library/papers/22327623 | PubMed |
| 15 | 31611986 | Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer. | Oncol Lett | 2019 | https://conductscience.org/library/papers/31611986 | PubMed |
| 16 | 31125062 | Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. | Ann Oncol | 2019 | https://conductscience.org/library/papers/31125062 | PubMed |
| 17 | 23242438 | Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. | J Thorac Oncol | 2013 | https://conductscience.org/library/papers/23242438 | PubMed |
| 18 | 21825258 | Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21825258 | PubMed |
| 19 | 27151654 | Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. | Oncologist | 2016 | https://conductscience.org/library/papers/27151654 | PubMed |
| 20 | 23630215 | Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23630215 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42453333 | Exploring the Impact of Multiple Gene Mutations on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Response in Asian Nonsmall Cell Lung Cancer Patients. | ACS Pharmacol Transl Sci | 2026 | https://conductscience.org/library/papers/42453333 | PubMed |
| 39421181 | Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review. | Ecancermedicalscience | 2024 | https://conductscience.org/library/papers/39421181 | PubMed |
| 36256645 | Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer. | PLoS One | 2022 | https://conductscience.org/library/papers/36256645 | PubMed |
| 34599863 | Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy. | Cancer Med | 2021 | https://conductscience.org/library/papers/34599863 | PubMed |
Genes31
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34599863
GET https://conductscience.org/api/papers/v1/34599863/references?page=2